Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer

Gefitinib (‘Iressa’, ZD1839) is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated antitumour activity and favourable tolerability in Phase II studies. We investigated whether EGFR expression levels could predict for response to gefitinib in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Parra, H S, Cavina, R, Latteri, F, Zucali, P A, Campagnoli, E, Morenghi, E, Grimaldi, G C, Roncalli, M, Santoro, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409824/
https://www.ncbi.nlm.nih.gov/pubmed/15187994
http://dx.doi.org/10.1038/sj.bjc.6601923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409824/
https://www.ncbi.nlm.nih.gov/pubmed/15187994
http://dx.doi.org/10.1038/sj.bjc.6601923

Ejemplares similares